{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:08:13Z","timestamp":1790899693754,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Funds"},{"name":"FCT \u2013 Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["UID\/Multi\/04546\/2013"],"award-info":[{"award-number":["UID\/Multi\/04546\/2013"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.jconrel.2018.12.049","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T11:45:36Z","timestamp":1546429536000},"page":"187-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":185,"special_numbering":"C","title":["Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis"],"prefix":"10.1016","volume":"295","author":[{"given":"C.","family":"Costa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.N.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Sousa Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6923-0232","authenticated-orcid":false,"given":"A.C.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.12.049_bb0005","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1039\/C6NR07581A","article-title":"Evidence of nose-to-brain delivery of nanoemulsions: cargoes but not vehicles","volume":"9","author":"Ahmad","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","article-title":"A review of intranasal formulations for the treatment of seizure emergencies","volume":"237","author":"Kapoor","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0015","first-page":"6553","article-title":"Intranasal lipid nanoparticles for the treatment of neurodegenerative diseases","author":"Cunha","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2017018693","article-title":"Lipid nanoparticles for nasal\/intranasal drug delivery","volume":"34","author":"Cunha","year":"2017","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yebeh.2003.10.005","article-title":"Epilepsy and anxiety","volume":"4","author":"Vazquez","year":"2003","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0030","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.yebeh.2016.03.020","article-title":"Anxiety disorders in people with epilepsy","volume":"59","author":"Brandt","year":"2016","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0035","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881105059253","article-title":"Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology","volume":"19","author":"Baldwin","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0040","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1006\/ebeh.2000.0080","article-title":"Epilepsy and anxiety","volume":"1","author":"Goldstein","year":"2000","journal-title":"Epilepsy & Behavior"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0045","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00726-006-0415-x","article-title":"Mechanisms regulating GABAergic inhibitory transmission in the basolateral amygdala: implications for epilepsy and anxiety disorders","volume":"32","author":"Aroniadou-Anderjaska","year":"2007","journal-title":"Amino Acids"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0050","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/10799890600920035","article-title":"GABAA receptors in central nervous system disease: anxiety, epilepsy, and insomnia","volume":"26","author":"Mohler","year":"2006","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0055","first-page":"72","article-title":"Intranasal administration of carbamazepine-loaded carboxymethyl. Chitosan nanoparticles for drug delivery to the brain","volume":"13","author":"Liu","year":"2017","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0060","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.yebeh.2015.04.027","article-title":"Intranasal therapies for acute seizures","volume":"49","author":"Kalviainen","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0065","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1080\/10717544.2016.1223216","article-title":"Intranasal brain-targeted clonazepam polymeric micelles for immediate control of status epilepticus: in vitro optimization, ex vivo determination of cytotoxicity, in vivo biodistribution and pharmacodynamics studies","volume":"23","author":"Nour","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40268-017-0219-3","article-title":"Intranasal therapy to stop status epilepticus in prehospital settings","volume":"18","author":"Benfield","year":"2018","journal-title":"Drugs R D"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0075","series-title":"Panic Attacks and Panic Disorder","author":"Smith","year":"2018"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0080","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1208\/s12249-015-0294-0","article-title":"Nose-to-brain delivery of PLGA-Diazepam nanoparticles","volume":"16","author":"Sharma","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0085","series-title":"Administration of Benzodiazepine Compositions","author":"Cartt","year":"2009"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0090","series-title":"Basic & Clinical Pharmacology","author":"Katzung","year":"2015"},{"issue":"9","key":"10.1016\/j.jconrel.2018.12.049_bb0095","author":"Food and Drug Administration","year":"2011","journal-title":"Alprazolam Tablets - Xanax\u00ae"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0100","series-title":"Diazepam Tablets - Valium\u00ae","author":"Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0105","author":"Food and Drug Administration","year":"2016","journal-title":"Lorazepam Tablets - Ativan\u00ae"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0110","series-title":"Midazolam Injection","author":"Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0115","author":"Food and Drug Administration","year":"2013","journal-title":"Clonazepam Tablets - Klonopin\u00ae"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nurt.2009.01.002","article-title":"Intranasal delivery of antiepileptic medications for treatment of seizures","volume":"6","author":"Wermeling","year":"2009","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejps.2014.04.019","article-title":"Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting","volume":"60","author":"Serralheiro","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0130","series-title":"Carbamazepine Tablets; Suspension - Tegretol\u00ae","author":"Food and Drug Administration","year":"2009"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0135","series-title":"Valproic Acid Solution; Capsules - Depakene\u00ae","author":"Food and Drug Administration","year":"2009"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0140","series-title":"Levetiracetam Accord","author":"European Medicines Agency","year":"2018"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0145","series-title":"Lamotrigine - Lamictal and associated names","author":"European Medicines Agency","year":"2008"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0150","author":"Food and Drug Administration","year":"2009","journal-title":"Phenytoin Capsule - Dilantin\u00ae"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0155","series-title":"Anxiety Medication","author":"Smith","year":"2018"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0160","series-title":"Standard Terms","author":"Council of Europe","year":"2017"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.tiv.2004.07.003","article-title":"The use of human nasal in vitro cell systems during drug discovery and development","volume":"19","author":"Dimova","year":"2005","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0170","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/10717544.2014.920431","article-title":"Nasal-nanotechnology: revolution for efficient therapeutics delivery","volume":"23","author":"Kumar","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0175","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10717544.2013.838713","article-title":"Insights into direct nose to brain delivery: current status and future perspective","volume":"21","author":"Mittal","year":"2014","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0180","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","article-title":"Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives","volume":"57","author":"Ugwoke","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0190","first-page":"208","article-title":"Nano formulation: A novel approach for nose to brain drug delivery","volume":"8","author":"Singh","year":"2016","journal-title":"J. Chem. Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0195","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.drudis.2015.10.016","article-title":"Smart materials: in situ gel-forming systems for nasal delivery","volume":"21","author":"Karavasili","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0200","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1517\/14712598.3.3.519","article-title":"Nasal drug delivery","volume":"3","author":"Suman","year":"2003","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0205","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejps.2016.05.008","article-title":"Non-invasive intranasal delivery of quetiapine fumarate loaded microemulsion for brain targeting: Formulation, physicochemical and pharmacokinetic consideration","volume":"91","author":"Shah","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0210","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0215","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1208\/s12248-015-9724-x","article-title":"Emerging insights for translational pharmacokinetic and pharmacokinetic-pharmacodynamic studies: towards prediction of nose-to-brain transport in humans","volume":"17","author":"Ruigrok","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0220","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.2174\/138920112803341752","article-title":"Drug delivery systems from nose to brain","volume":"13","author":"Misra","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0230","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1007\/s10439-008-9556-2","article-title":"Effects of differences in nasal anatomy on airflow distribution: a comparison of four individuals at rest","volume":"36","author":"Segal","year":"2008","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0235","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3109\/03639045.2015.1052081","article-title":"Nanoneurotherapeutics approach intended for direct nose to brain delivery","volume":"41","author":"Md","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0240","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejps.2010.05.003","article-title":"Strategy for effective brain drug delivery","volume":"40","author":"Alam","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0245","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S1359-6446(02)02529-1","article-title":"Nasal drug delivery: new developments and strategies","volume":"7","author":"Illum","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0250","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery--possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0255","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids","volume":"134","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0260","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0091-6749(83)90518-3","article-title":"Nasal anatomy, physiology, and function","volume":"72","author":"Geurkink","year":"1983","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0265","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40263-016-0405-9","article-title":"Crossing the blood-brain barrier: recent advances in drug delivery to the brain","volume":"31","author":"Patel","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0270","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","article-title":"Transport of drugs across the blood-brain barrier by nanoparticles","volume":"161","author":"Wohlfart","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0275","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1208\/s12248-015-9719-7","article-title":"Intranasal delivery of proteins and peptides in the treatment of neurodegenerative diseases","volume":"17","author":"Meredith","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0280","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/jps.21924","article-title":"Intranasal delivery to the central nervous system: mechanisms and experimental considerations","volume":"99","author":"Dhuria","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0285","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2014.06.053","article-title":"Quantitative analysis of drug delivery to the brain via nasal route","volume":"189","author":"Kozlovskaya","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0290","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.drudis.2018.01.005","article-title":"An update on the role of nanovehicles in nose-to-brain drug delivery","volume":"23","author":"Feng","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0295","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","article-title":"Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs","volume":"281","author":"Agrawal","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0300","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ejpb.2018.05.009","article-title":"Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics","volume":"128","author":"Bourganis","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0305","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: physicochemical and therapeutic aspects","volume":"337","author":"Costantino","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0315","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1359-6446(02)02452-2","article-title":"Permeability issues in nasal drug delivery","volume":"7","author":"Arora","year":"2002","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0320","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2015.01.025","article-title":"Solid microparticles based on chitosan or methyl-beta-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate","volume":"201","author":"Rassu","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0325","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1023\/A:1025053115583","article-title":"P-Glycoprotein attenuates brain uptake of substrates after nasal instillation","volume":"20","author":"Graff","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0330","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/jcbfm.2013.41","article-title":"Accessing the brain: the nose may know the way","volume":"33","author":"Djupesland","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0335","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","article-title":"Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review","volume":"3","author":"Djupesland","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0340","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.msec.2016.05.119","article-title":"Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies","volume":"68","author":"Geszke-Moritz","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0345","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","article-title":"Nanostructured lipid carriers: promising drug delivery systems for future clinics","volume":"12","author":"Beloqui","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0350","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejps.2017.11.023","article-title":"Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: a review","volume":"112","author":"Garc\u00eas","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0355","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jddst.2017.09.022","article-title":"Nano-carrier enabled drug delivery systems for nose to brain targeting for the treatment of neurodegenerative disorders","volume":"43","author":"Md","year":"2018","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0360","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2017.09.001","article-title":"Progress in brain targeting drug delivery system by nasal route","volume":"268","author":"Khan","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0365","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.drudis.2015.10.016","article-title":"Smart materials: in situ gel-forming systems for nasal delivery","volume":"21","author":"Karavasili","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0370","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejpb.2017.10.008","article-title":"In situ mucoadhesive-thermosensitive liposomal gel as a novel vehicle for nasal extended delivery of opiorphin","volume":"122","author":"Mura","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0375","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jddst.2015.05.002","article-title":"Particulate formulations based on chitosan for nose-to-brain delivery of drugs. A review","volume":"32","author":"Rassu","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0380","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.carbpol.2018.07.054","article-title":"Box-Behnken design optimization of mucoadhesive chitosan-coated nanoemulsions for rosmarinic acid nasal delivery\u2014in vitro studies","volume":"199","author":"Fachel","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0385","doi-asserted-by":"crossref","first-page":"7185","DOI":"10.2174\/138161281941131219123329","article-title":"Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and schizophrenia","volume":"19","author":"Silva","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0390","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.2174\/092986712803251584","article-title":"Lipid-based nanocarriers as an alternative for oral delivery of poorly water- soluble drugs: peroral and mucosal routes","volume":"19","author":"Silva","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0395","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/591325","article-title":"Liposome technology for industrial purposes","volume":"2011","author":"Wagner","year":"2011","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0400","doi-asserted-by":"crossref","first-page":"10938","DOI":"10.1021\/acs.chemrev.5b00046","article-title":"New developments in liposomal drug delivery","volume":"115","author":"Pattni","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0405","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0410","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1389201015666141229103709","article-title":"Lipid nanoparticles for the delivery of biopharmaceuticals","volume":"16","author":"Silva","year":"2015","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0415","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art","volume":"50","author":"Muller","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0420","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/157016311796799062","article-title":"20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications","volume":"8","author":"Muller","year":"2011","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0425","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.nano.2015.09.004","article-title":"Nanostructured lipid carriers: promising drug delivery systems for future clinics","volume":"12","author":"Beloqui","year":"2016","journal-title":"Nanomedicine"},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2018.12.049_bb0430","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations","volume":"54","author":"Muller","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0435","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.2174\/138161282343180215151302","article-title":"Editorial: applications of Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): State of the Art","volume":"23","author":"Silva","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0440","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2012.09.021","article-title":"Solid lipid nanoparticles: production, characterization and applications","volume":"64","author":"Mehnert","year":"2012","journal-title":"Adv. Drug Deliver. Rev."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0445","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jconrel.2017.03.008","article-title":"Nanoemulsion: Concepts, development and applications in drug delivery","volume":"252","author":"Singh","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0450","doi-asserted-by":"crossref","first-page":"R635","DOI":"10.1088\/0953-8984\/18\/41\/R01","article-title":"Nanoemulsions: formation, structure, and physical properties","volume":"18","author":"Mason","year":"2006","journal-title":"J. Phys. Condens. Matter"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0455","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s11095-010-0309-1","article-title":"Nano-emulsions and micro-emulsions: clarifications of the critical differences","volume":"28","author":"Anton","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0460","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.addr.2012.09.018","article-title":"Microemulsion-based media as novel drug delivery systems","volume":"64","author":"Lawrence","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0465","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijpharm.2017.05.005","article-title":"Microemulsion utility in pharmaceuticals: implications for multi-drug delivery","volume":"526","author":"Callender","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0470","first-page":"8","article-title":"Nanoemulsions versus microemulsions: terminology, differences, and similarities","volume":"2012","author":"McClements","year":"1719","journal-title":"Soft Matter"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0475","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.2174\/0929867323666160824162401","article-title":"therapeutic strategies for alzheimer's and parkinson's diseases by means of drug delivery systems","volume":"23","author":"Cunha","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0480","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1389201015666141229103709","article-title":"Lipid nanoparticles for the delivery of biopharmaceuticals","volume":"16","author":"Ana","year":"2015","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0485","doi-asserted-by":"crossref","DOI":"10.4103\/0975-8453.59509","article-title":"Nanoemulsion: a pharmaceutical review","volume":"1","author":"Shah","year":"2010","journal-title":"Syst. Rev. Pharm."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0490","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1208\/s12249-009-9197-2","article-title":"Diazepam-loaded solid lipid nanoparticles: design and characterization","volume":"10","author":"Abdelbary","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0495","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s13346-012-0110-2","article-title":"SLN approach for nose-to-brain delivery of alprazolam","volume":"2","author":"Singh","year":"2012","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0500","first-page":"363","article-title":"Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model","volume":"6","author":"Eskandari","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0505","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1517\/17425247.2014.945416","article-title":"Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy","volume":"12","author":"Alam","year":"2015","journal-title":"Exp. Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0510","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.xphs.2018.04.007","article-title":"Superparamagnetic iron oxide\u2013loaded lipid nanocarriers incorporated in thermosensitive in situ gel for magnetic brain targeting of clonazepam","volume":"107","author":"Abbas","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0515","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/jps.20480","article-title":"Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting","volume":"95","author":"Vyas","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0520","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/jps.22307","article-title":"Intranasal clobazam delivery in the treatment of status epilepticus","volume":"100","author":"Florence","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0525","first-page":"642","article-title":"Preparation of lorazepam-loaded microemulsions for intranasal delivery and its pharmacokinetics","volume":"64","author":"Yao","year":"2009","journal-title":"Pharmazie"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0530","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bfopcu.2013.07.002","article-title":"Formulation consideration and characterization of microemulsion drug delivery system for transnasal administration of carbamazepine","volume":"51","author":"Patel","year":"2013","journal-title":"Bull. Facult. Pharm. Cairo Univ."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0535","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/10717544.2014.908980","article-title":"Microemulsion-based drug delivery system for transnasal delivery of Carbamazepine: preliminary brain-targeting study","volume":"23","author":"Patel","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0540","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s13346-012-0126-7","article-title":"Development of carbamazepine transnasal microemulsion for treatment of epilepsy","volume":"3","author":"Acharya","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0545","first-page":"64","article-title":"Preparation and evaluation of transnasal microemulsion of carbamazepine","volume":"8","author":"Acharya","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0550","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejps.2018.05.019","article-title":"Preparation of (99m)Tc-levetiracetam intranasal microemulsion as the first radiotracer for SPECT imaging of the Synaptic Vesicle Protein SV2A","author":"Rashed","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0555","first-page":"1","article-title":"Brain targeting of chitosan-based diazepam mucoadhesive microemulsions via nasal route: formulation optimization, characterization, pharmacokinetic and pharmacodynamic evaluation","author":"Ramreddy","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0560","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejps.2015.07.002","article-title":"Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters","volume":"78","author":"Shah","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0565","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.colsurfb.2014.06.037","article-title":"Surface engineered nanostructured lipid carriers for efficient nose to brain delivery of ondansetron HCl using Delonix regia gum as a natural mucoadhesive polymer","volume":"122","author":"Devkar","year":"2014","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0570","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.colsurfb.2015.06.054","article-title":"Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration","volume":"134","author":"Gartziandia","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0575","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.colsurfb.2013.09.030","article-title":"Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment","volume":"113","author":"Sood","year":"2014","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2018.12.049_bb0580","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijpharm.2017.07.030","article-title":"Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion","volume":"529","author":"Abdou","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0585","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2174\/1567201813666151202195729","article-title":"Nanoemulsions for intranasal delivery of riluzole to improve brain bioavailability: formulation development and pharmacokinetic studies","volume":"13","author":"Parikh","year":"2016","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0590","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.carbpol.2013.08.027","article-title":"Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats","volume":"99","author":"Bshara","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0595","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1007\/s11095-015-1744-9","article-title":"Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer's disease","volume":"32","author":"Zheng","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0600","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","article-title":"Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration","volume":"452","author":"Yang","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2018.12.049_bb0605","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.colsurfb.2018.11.025","article-title":"Lamotrigine encapsulated intra-nasal nanoliposome formulation for epilepsy treatment: formulation design, characterization and nasal toxicity study","volume":"174","author":"Praveen","year":"2019","journal-title":"Colloids Surf. B: Biointerfaces"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918307545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918307545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:38:46Z","timestamp":1759160326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918307545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":120,"alternative-id":["S0168365918307545"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.12.049","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.12.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}